Published in Clin Med Insights Arthritis Musculoskelet Disord on January 05, 2012
An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int (2006) 11.05
Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med (2001) 9.57
Hip fractures in the elderly: a world-wide projection. Osteoporos Int (1992) 9.08
Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med (2007) 7.38
2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ (2010) 6.37
Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res (2010) 6.00
European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int (2008) 5.27
Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int (2000) 4.85
Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int (2008) 4.73
Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res (2004) 4.04
Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res (1998) 3.65
Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther (2001) 3.59
Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. J Am Dent Assoc (2006) 3.41
Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA (2010) 3.37
Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas (2009) 2.74
The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci U S A (2006) 2.73
Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int (2008) 2.72
Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: a clinical practice guideline from the American College of Physicians. Ann Intern Med (2008) 2.69
Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause (2010) 2.53
Increased mortality in patients with a hip fracture-effect of pre-morbid conditions and post-fracture complications. Osteoporos Int (2007) 2.46
Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture. Ann Intern Med (2008) 2.40
Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int (2006) 2.34
The prevention of hip fracture with risedronate and ergocalciferol plus calcium supplementation in elderly women with Alzheimer disease: a randomized controlled trial. Arch Intern Med (2005) 2.02
Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev (2008) 2.00
Excess mortality following hip fracture: the role of underlying health status. Osteoporos Int (2007) 1.86
The risk and burden of vertebral fractures in Sweden. Osteoporos Int (2003) 1.74
Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int (2003) 1.65
The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int (2002) 1.61
Postmarketing surveillance rates of uveitis and scleritis with bisphosphonates among a national veteran cohort. Retina (2008) 1.59
Risedronate therapy for prevention of hip fracture after stroke in elderly women. Neurology (2005) 1.55
Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old. J Am Geriatr Soc (2004) 1.44
Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res (2005) 1.42
Tolerability of risedronate in postmenopausal women intolerant of alendronate. Aging (Milano) (2001) 1.40
Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD. J Bone Miner Res (2005) 1.39
Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporos Int (2009) 1.39
The influence of pyrophosphate, condensed phosphates, phosphonates and other phosphate compounds on the dissolution of hydroxyapatite in vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomised rats. Calcif Tissue Res (1970) 1.35
Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone (2003) 1.34
Yearly zoledronic acid in postmenopausal osteoporosis. N Engl J Med (2007) 1.29
Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday. Osteoporos Int (2008) 1.24
Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis. Ther Clin Risk Manag (2010) 1.12
Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials. Mayo Clin Proc (2002) 1.07
The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis. Semin Arthritis Rheum (2010) 1.04
Lifetime and five-year age-specific risks of first and subsequent osteoporotic fractures in postmenopausal women. Osteoporos Int (2001) 0.99
Hip and non-spine fracture risk reductions differ among antiresorptive agents: Evidence from randomised controlled trials. Int J Clin Pract (2006) 0.97
Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club. Osteoporos Int (2010) 0.97
Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium. Pharmacoeconomics (2011) 0.96
Liver damage due to alendronate. N Engl J Med (2000) 0.92
Risedronate-induced Hepatitis. Am J Med (2007) 0.91
RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction. Osteoporos Int (2008) 0.91
Impact of noncompliance with alendronate and risedronate on the incidence of nonvertebral osteoporotic fractures in elderly women. Br J Clin Pharmacol (2008) 0.90
Bilateral uveitis secondary to bisphosphonate therapy. Ophthalmologica (2009) 0.85
Treatment of osteoporosis: recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity. Osteoporos Int (2009) 0.85
Reducing hip fracture risk with risedronate in elderly women with established osteoporosis. Clin Interv Aging (2009) 0.84
Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis. Curr Med Res Opin (2004) 0.84
Updated recommendations for the diagnosis and management of osteoporosis: a local perspective. Ann Saudi Med (2011) 0.81
An observational study of musculoskeletal pain among patients receiving bisphosphonate therapy. Mayo Clin Proc (2010) 0.79
Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis. Osteoporos Int (2007) 0.79
Health-economic comparison of three recommended drugs for the treatment of osteoporosis. Int J Clin Pharmacol Res (2004) 0.76
Efficacy and acceptability of risedronate 5 mg daily compared with 35 mg once weekly for the treatment of postmenopausal osteoporosis. Climacteric (2006) 0.76
Risedronate versus alendronate in older patients with osteoporosis at high risk of fracture: an Italian cost-effectiveness analysis. Aging Clin Exp Res (2010) 0.76
Development of a new sensitive and efficient multiplex polymerase chain reaction (PCR) for identification and differentiation of different mycobacterial species. Trop Med Int Health (2003) 0.90
Characterization of the surface properties of a model pharmaceutical fine powder modified with a pharmaceutical lubricant to improve flow via a mechanical dry coating approach. J Pharm Sci (2011) 0.89
Structural characterization and spectroelectrochemical, anion sensing and solvent dependence photophysical studies of a bimetallic Ru(II) complex derived from 1,3-di(1H-imidazo[4,5-f][1,10]phenanthroline-2-yl)benzene. Dalton Trans (2012) 0.87
Adult onset spinocerebellar ataxia in a Canadian movement disorders clinic. Can J Neurol Sci (2005) 0.86
Sex differences in smiling and other photographed traits: a theoretical assessment. J Biosoc Sci (2010) 0.80
Magnesium stearate increases salbutamol sulphate dispersion: what is the mechanism? Int J Pharm (2009) 0.78
Management of osteoporosis in elderly men. Maturitas (2011) 0.77
Maternal smoking during pregnancy and self-reported delinquency by offspring. Crim Behav Ment Health (2012) 0.76
Ytterbium-sensitized Thulium-doped fiber laser in the near-IR with 980 nm pumping. Opt Express (2010) 0.75
A terpyridyl-imidazole (tpy-HImzPh3) based bifunctional receptor for multichannel detection of Fe2+ and F- ions. Dalton Trans (2011) 0.75
Fabrication of ultra-high numerical aperture GeO2-doped fiber and its use for broadband supercontinuum generation. Appl Opt (2017) 0.75
Eye color, hair color, blood type, and the rhesus factor: exploring possible genetic links to sexual orientation. Arch Sex Behav (2008) 0.75
Ru-Os dyads based on a mixed bipyridine-terpyridine bridging ligand: modulation of the rate of energy transfer and pH-induced luminescence switching in the infrared domain. Dalton Trans (2017) 0.75
Delinquency, androgens, and the family: a test of evolutionary neuroandrogenic theory. Int J Offender Ther Comp Criminol (2012) 0.75
Near-infrared supercontinnum generation in single-mode nonlinear Yb(3+)-doped fiber amplifier. Opt Express (2014) 0.75
Luminescent bis-tridentate ruthenium(II) and osmium(II) complexes based on terpyridyl-imidazole ligand: synthesis, structural characterization, photophysical, electrochemical, and solvent dependence studies. Dalton Trans (2012) 0.75